Detection of antibody-dependent complement-mediated inactivation of both autologous and heterologous virus in primary human immunodeficiency virus type 1 infection.
about
Extensive complement-dependent enhancement of HIV-1 by autologous non-neutralising antibodies at early stages of infectionComplement Protein C1q Inhibits Antibody-Dependent Enhancement of Flavivirus Infection in an IgG Subclass-Specific MannerComplement modulates pathogenesis and antibody-dependent neutralization of West Nile virus infection through a C5-independent mechanismProgress on the development of therapeutics against West Nile virusComplement and its role in protection and pathogenesis of flavivirus infectionsThe good and evil of complement activation in HIV-1 infectionComplement lysis activity in autologous plasma is associated with lower viral loads during the acute phase of HIV-1 infectionSurvivors Remorse: antibody-mediated protection against HIV-1.Production and characterization of high-affinity human monoclonal antibodies to human immunodeficiency virus type 1 envelope glycoproteins in a mouse model expressing human immunoglobulins.Preclinical studies of human immunodeficiency virus/AIDS vaccines: inverse correlation between avidity of anti-Env antibodies and peak postchallenge viremia.An antibody-recruiting small molecule that targets HIV gp120.V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144.In vivo emergence of HIV-1 highly sensitive to neutralizing antibodiesCD8+ and CD20+ lymphocytes cooperate to control acute simian immunodeficiency virus/human immunodeficiency virus chimeric virus infections in rhesus monkeys: modulation by major histocompatibility complex genotypeUnique C2V3 sequence in HIV-1 envelope obtained from broadly neutralizing plasma of a slow progressing patient conferred enhanced virus neutralization.Genomic analysis reveals pre- and postchallenge differences in a rhesus macaque AIDS vaccine trial: insights into mechanisms of vaccine efficacyComplement and HIV-I infection/HIV-associated neurocognitive disorders.The immune response during acute HIV-1 infection: clues for vaccine development.A high-affinity inhibitor of human CD59 enhances complement-mediated virolysis of HIV-1: implications for treatment of HIV-1/AIDSDecreased Fc receptor expression on innate immune cells is associated with impaired antibody-mediated cellular phagocytic activity in chronically HIV-1 infected individuals.Lack of protection following passive transfer of polyclonal highly functional low-dose non-neutralizing antibodiesNeutralizing and other antiviral antibodies in HIV-1 infection and vaccination.Lysis of human immunodeficiency virus type 1 by a specific secreted human phospholipase A2Potent autologous and heterologous neutralizing antibody responses occur in HIV-2 infection across a broad range of infection outcomes.A replication-competent adenovirus-human immunodeficiency virus (Ad-HIV) tat and Ad-HIV env priming/Tat and envelope protein boosting regimen elicits enhanced protective efficacy against simian/human immunodeficiency virus SHIV89.6P challenge in rhePolyfunctional HIV-Specific Antibody Responses Are Associated with Spontaneous HIV Control.Nonneutralizing antibodies binding to the surface glycoprotein of lymphocytic choriomeningitis virus reduce early virus spread.Effect of complement on HIV-2 plasma antiviral activity is intratype specific and potent.Potent human immunodeficiency virus-neutralizing and complement lysis activities of antibodies are not obligatorily linkedStimulation of the primary anti-HIV antibody response by IFN-alpha in patients with acute HIV-1 infection.Opportunities to exploit non-neutralizing HIV-specific antibody activity.Special anniversary review: twenty-five years of human immunodeficiency virus research: successes and challenges.Role of complement and antibodies in controlling infection with pathogenic simian immunodeficiency virus (SIV) in macaques vaccinated with replication-deficient viral vectors.Matrix metalloprotease inhibitors restore impaired NK cell-mediated antibody-dependent cellular cytotoxicity in human immunodeficiency virus type 1 infection.Resistance of Transmitted Founder HIV-1 to IFITM-Mediated Restriction.Human immunodeficiency virus antibodies and the vaccine problem.Engineering broadly neutralizing antibodies for HIV prevention and therapy.Enhanced phagocytic activity of HIV-specific antibodies correlates with natural production of immunoglobulins with skewed affinity for FcγR2a and FcγR2b.Specific interaction of hepatitis C virus glycoproteins with mannan binding lectin inhibits virus entry.Antibody-based HIV-1 vaccines: recent developments and future directions.
P2860
Q21245045-06632031-9F40-49EC-9A17-D6535419448BQ27485131-7A495B1B-9277-4F64-ADBE-810C9228D989Q27489809-8B6DDE7A-E83E-4185-8D05-B6353E5991D6Q27489893-54B4AFD7-D70F-4ED3-9DDD-EE122EE5E6E2Q27490236-96A3CFFB-0169-4DB9-BF97-63D76228F6F1Q28275986-B640D819-A19F-426E-8201-4D3D562CF503Q28766705-8F0A50AA-C163-4597-A645-6D3227E057B5Q30238730-6D764F56-6D0F-412B-8476-3F233E5977ABQ30358769-1EA0B2D8-5B73-4D61-8A5C-AFADE9A998C0Q30374995-7D16E271-2FD7-49EE-847D-264A7DB8FA07Q30381757-11930A7D-E708-4423-913D-1DFD5FDC8775Q33874253-DDD64EAC-6E2F-4A1B-9F15-4B4DFCCA11B5Q34009730-D57AA0F9-99BB-40B5-8DBE-FC45602CAF99Q34142932-B57CBAA8-C76C-49D5-81DA-5AEF23DDA3D3Q34441935-B2AA667F-914E-49BD-9E9A-9D6E9C65AC49Q34485178-90E58A25-6F6E-448C-A557-06B9961AFA29Q34610122-7C27FD10-FD71-4B28-A281-3DC04A8DF519Q34614862-3D965608-DCA9-4261-B781-0889F358A335Q34749137-6A2F39C1-D37C-42F6-BCDC-78B0F39039D3Q35037803-0ABF7644-84BC-4D37-8C36-CF19CE90CA64Q35167400-4F06FF2D-1F49-4F5F-8878-05978CB60534Q35208657-863C751D-D2DE-4D62-930D-37209F3C64A0Q35635168-A84A1DE3-BB54-4F8D-B5AE-C2332A2824D6Q35665765-686150C2-6B43-4E8D-B758-5C5606B879D3Q35785031-50AD85FC-711A-4E53-AE99-E9676A912E13Q35888710-9EC0DEF2-E0C9-465A-992D-709CA424FA1FQ36228781-EF717173-3BF7-4B62-93F5-3598B2C3B8E4Q36506821-810C18F2-E2B4-4C03-BFF8-1DF94B458225Q36540060-9B28CE19-6371-4E4D-8247-957E70E7FA30Q36568672-8F3CB722-ED67-4D3A-AD3D-57E28D697519Q37113941-BE11F83D-DEE4-42A9-9752-42BA83F03110Q37121901-C7B0278C-02B8-46A5-9041-4EC6E92EF814Q37268317-48BF087A-C21A-4DEA-8798-1C7196563FA2Q37333777-88541548-EB23-4B3B-9B26-FB9B3A71A197Q37359047-A5D6347A-DAA3-4F20-9B20-0BEB08ED9341Q38192126-EA0AF0F2-2633-4E2D-A6B3-EF44F33FC39BQ38717198-770DAFD5-1B1C-4715-972C-AFD297F9A5D0Q40529181-4CFC5753-1815-4BD1-8C1C-539C93AB3931Q42024261-4428511F-20E8-491E-BE60-3697FB5573B2Q42738983-090C6D60-68C5-4426-BA9A-35D4C148CA73
P2860
Detection of antibody-dependent complement-mediated inactivation of both autologous and heterologous virus in primary human immunodeficiency virus type 1 infection.
description
2005 nî lūn-bûn
@nan
2005 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի մարտին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Detection of antibody-dependen ...... ciency virus type 1 infection.
@ast
Detection of antibody-dependen ...... ciency virus type 1 infection.
@en
type
label
Detection of antibody-dependen ...... ciency virus type 1 infection.
@ast
Detection of antibody-dependen ...... ciency virus type 1 infection.
@en
prefLabel
Detection of antibody-dependen ...... ciency virus type 1 infection.
@ast
Detection of antibody-dependen ...... ciency virus type 1 infection.
@en
P2093
P2860
P1433
P1476
Detection of antibody-dependen ...... ciency virus type 1 infection.
@en
P2093
Aine McKnight
David Cornforth
Ian Williams
Keith Aubin
Mailee Wong
Marlén M I Aasa-Chapman
Nicola A Jones
Persephone Borrow
Philippa Newton
Pierre Pellegrino
P2860
P304
P356
10.1128/JVI.79.5.2823-2830.2005
P577
2005-03-01T00:00:00Z